The Future of Oncology Research in a Shifting Policy Landscape

EP: 1.Impact of Recent Policies on US Health Care System and Oncology Practice

EP: 2.Bridging Policy Change With Patient Access and Care Delivery in Oncology

EP: 3.Role of Pharmacy Benefit Managers in Oncology

EP: 4.Impact of Utilization Management Policies in Oncology

EP: 5.Challenges of Step Edits in Oncology

EP: 6.Understanding Gaps in Aligning Coverage Policy With Innovation in Oncology

EP: 7.Disconnect Between NCCN Guidelines and Coverage Decisions With BTK Inhibitors in CLL

EP: 8.Impact of Evidence-Coverage Misalignment on Patient Outcomes With BTK Inhibitors in CLL

EP: 9.Using Real-World Evidence of BTK Inhibitors to Inform Coverage Decisions in CLL

EP: 10.Balancing Black Box Warnings With Real-World Oncology Practice

EP: 11.Impact of Utilization Management on Physician Autonomy and Shared Decision-Making in Oncology

EP: 12.Shaping Oncology Policy Through Access and Safety Considerations

EP: 13.Impact of Inflation Reduction Act and the Drug Price Negotiation Program in Oncology

EP: 14.Implications of IRA Drug Pricing Negotiations on BTK Inhibitors in CLL

Now Viewing

EP: 15.The Future of Oncology Research in a Shifting Policy Landscape

Panelists discuss how evolving policy environments will shape the future of oncology research, access, and innovation. They predict that pricing reforms, value-based reimbursement, and real-world evidence integration will redefine how new therapies are developed and evaluated.

Collaborative partnerships between government, academia, and industry will be essential to sustaining innovation while meeting affordability demands. Panelists emphasize the need to streamline trial design, accelerate data sharing, and foster transparency to adapt to the rapidly changing policy landscape.

Ultimately, they express optimism that thoughtful regulation can catalyze—not constrain—scientific progress, ensuring patients continue to benefit from cutting-edge oncology advancements.